The shares of medmix AG – leader in high-precision delivery devices in healthcare, industrial and consumer end-markets – were traded at SIX for the first time today. The spin-off from Swiss industrial group Sulzer was completed by means of a demerger whereas existing Sulzer shareholders received one medmix share in addition to each Sulzer share held.
The company’s existing issued share capital comprised of 34,262,370 registered shares. In addition, 7,000,000 newly issued registered shares were offered and placed. At an issue price of CHF 45.00 per registered share, the placement volume was CHF 315 million. Such newly issued registered shares will commence trading on 1 October 2021.
Girts Cimermans, CEO medmix, says: “I would like to thank the medmix and Sulzer teams for their combined efforts in making medmix’s incorporation and listing such a great success. We are extremely happy to see the trust and enthusiasm that the market and our investors have placed in us for medmix’s new beginning as an independent company. We look forward to building on what we have achieved so far to continue medmix’s successful development with renewed focus on our core markets and our loyal customers.”
Jos Dijsselhof, CEO SIX, says: “I am pleased to welcome medmix AG to SIX. This listing adds another global market leader in its field to our exchange and further increases our peer group of listed companies from the industrial sector. We wish medmix AG every success as a SIX-listed company.”
For more information about medmix, please see www.medmix.swiss